<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289301</url>
  </required_header>
  <id_info>
    <org_study_id>Polyoma IFB 29</org_study_id>
    <nct_id>NCT01289301</nct_id>
  </id_info>
  <brief_title>Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant</brief_title>
  <acronym>BKVIRUS</acronym>
  <official_title>Polyomavirus BK Nephropathy After Renal Transplantation: Randomized Clinical Trial to Demonstrate That Switching to mTOR Inhibitor is More Effective Than a Reduction of Immunosuppressive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polyomavirus BK nephropathy is a serious complication after renal transplantation leading to
      graft loss in 40% of cases. Since no virustatic drug exists, the investigators want to study
      the best way to manage viral invasion by changing the immunosuppressive treatment comparing
      two treatment schemes. The investigators hypothesis is that switching to an mTOR-based scheme
      is superior to a general decrease of a calcineurin inhibitor (CNI)-based scheme. The study
      will be performed as a prospective, randomized, parallel group comparison.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study group (n=62) will be switched from CNI to everolimus while the control group (n=62)
      will get a general reduction of the CNI-based immunosuppression. Follow-up and duration of
      intervention per patient will be 24 months, duration of the trial 72 months including 4 years
      of recruitment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>death or graft loss</measure>
    <time_frame>2 years of observation</time_frame>
    <description>after experimental intervention (switch to mTOR inhibitor in group 1) and control intervention (general reduction of immunosuppression) observation of graft function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>decrease of polyomavirus serum PCR</measure>
    <time_frame>2 years</time_frame>
    <description>regular measurement of polyomavirus serum PCR (every 4 weeks to 3 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decrease of creatinine</measure>
    <time_frame>2 years observation</time_frame>
    <description>regular measurment of graft function (every 4 weeks to 3 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression of chronic changes in renal histology</measure>
    <time_frame>renal biopsy 3 months after intervention</time_frame>
    <description>renal rebiopsy and comparison of chronic changes in renal biopsy with the diagnostic renal biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of rejections following intervention</measure>
    <time_frame>2 years after intervention</time_frame>
    <description>biopsy-verified rejections (graft biopsies on indication) may be a consequence of changement of immunosuppression and a side effect of it, rejections will be counted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>increase of BKV-specific T-cells</measure>
    <time_frame>2 years observation</time_frame>
    <description>increase of BKV-specific T-cells are a sign of overcoming viral infection and will be counted regularly (every 3 to 6 months)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Disorder Related to Renal Transplantation</condition>
  <condition>Immunosuppression Related Infectious Disease</condition>
  <condition>Virus Diseases</condition>
  <arm_group>
    <arm_group_label>mTOR-receiving arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>switching from calcineurin-inhibitor-based immunosuppression to mTOR-based immunosuppression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>calcineurin-inhibitor keeping arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>continuing calcineurin-inhibitor based immunosuppression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mTOR inhibitor (everolimus)</intervention_name>
    <description>calcineurin-inhibitor based immunosuppression will be switched to immunosuppression based on m-TOR inhibitor (everolimus trough level 3-7ng/mL)</description>
    <arm_group_label>mTOR-receiving arm</arm_group_label>
    <other_name>switch immunosuppression to everolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine or tacrolimus</intervention_name>
    <description>calcineurin inhibitor (cyclosporine or tacrolimus) will be continued (trough level 60-90ng/mL resp 3-7ng/mL)</description>
    <arm_group_label>calcineurin-inhibitor keeping arm</arm_group_label>
    <other_name>keeping immunosuppression with calcineurin inhibitor</other_name>
    <other_name>cyclosporine</other_name>
    <other_name>tacrolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  preceding renal transplantation

          -  functioning graft with a permanent creatinine clearance of more than 25mL/min

          -  biopsy-confirmed polyoma BK virus nephropathy

          -  age over 18 years old

        Exclusion Criteria:

          -  allergy or non-tolerance of the study medication everolimus

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anke Schwarz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School, Nephrology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hermann Haller, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School, Nephrology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia Linnenweber, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Hannover Medical School, Nephrology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armin Koch, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Hannover Medical School, Biometry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Heim, PD Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Hannover Medical School, Virology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Verena Broecker, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Hannover Medical School, Pathology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anke Schwarz, Prof. Dr.</last_name>
    <phone>+49 511 532 2329</phone>
    <email>schwarz.anke@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hermann Haller, Prof. Dr.</last_name>
    <phone>+49 511 5326319</phone>
    <email>haller.hermann@mh-hannover.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Freiburg, Transplant Outpatient Clinic</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>D-79104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerd Walz, Prof. Dr.</last_name>
      <phone>0761 2703250</phone>
      <email>gerd.walz@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Erlangen/ Nürnberg, Transplant Outpatient Clinic</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl Hilgers, Prof. Dr.</last_name>
      <phone>+49 9131 8536267</phone>
      <email>karl.hilgers@uk-erlangen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School, Transplant Outpatient Clinic</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anke Schwarz, Prof. Dr.</last_name>
      <phone>+49 511 5322329</phone>
      <email>schwarz.anke@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Silvia Linnenweber, Dr.</last_name>
      <phone>+49 511 5323000</phone>
      <email>linnenweber.silvia@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Essen, Transplant Outpatient Clinic</name>
      <address>
        <city>Essen</city>
        <state>Ruhrgebiet</state>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oliver Witzke, Prof. Dr.</last_name>
      <phone>+49 201 7231868</phone>
      <email>nephrologie@uk-essen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <last_update_submitted>February 2, 2011</last_update_submitted>
  <last_update_submitted_qc>February 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Clinical Research Center</name_title>
    <organization>Medizinische Hochschule</organization>
  </responsible_party>
  <keyword>renal transplantation</keyword>
  <keyword>polyoma BK virus infection</keyword>
  <keyword>everolimus</keyword>
  <keyword>calcineurin inhibitor</keyword>
  <keyword>mTOR inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

